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Wild poliovirus–associated paralytic poliomyelitis has 
not been reported in Australia since 1977. We report type 
1 wild poliovirus infection in a man who had traveled from 
Pakistan to Australia in 2007. Poliomyelitis should be consid-
ered for patients with acute ﬂ  accid paralysis or unexplained 
fever who have been to poliomyelitis-endemic countries.
T
he World Health Organization declared the Western 
Paciﬁ  c region, including Australia, polio free in 2000 
(1). The last known case of wild poliomyelitis in Austra-
lia occurred in 1977 (2). The National Polio Reference 
Laboratory (NPRL), in collaboration with the Australian 
Paediatric Surveillance Unit, coordinates surveillance for 
acute ﬂ  accid paralysis in children <15 years of age and in-
vestigates all suspected cases of polio (3). However, with 
increasing time since widespread poliomyelitis occurred in 
Australia, concern has been raised about whether poliomy-
elitis would be recognized (4). Indeed, we report a Paki-
stani patient in whom poliomyelitis was ﬁ  rst considered 
only after magnetic resonance imaging (MRI).
The Study
The patient was a 22-year-old Pakistani student in 
Melbourne, Australia; he had received at least 3 doses 
of oral polio vaccine as a child. On March 13, 2007, the 
student returned home to Kharian, Pakistan, to recuper-
ate from herpes zoster, which had developed in Febru-
ary 2007. From June 4 through June 7, he toured the 
North West Frontier Province of Pakistan, then returned 
to Kharian. On June 22, he felt unusually hot. Over the 
next 2 days he had fever, diaphoresis, nausea, vomiting, 
and pain in his low back and legs. On June 24, he noted 
lower limb weakness, especially in his left leg. He was 
not hospitalized, and after several days, all symptoms 
except the pain resolved. On July 2, he traveled back to 
Melbourne.
Starting on July 3, the patient’s pain increased and 
lower limb weakness subsequently returned, accompanied 
by upper limb tremors. He had neither systemic symptoms 
nor bladder or bowel dysfunction. He was referred to Box-
hill Hospital, Eastern Health, emergency department on 
July 6. Physical examination found that the patient’s legs 
were tender to palpation and that strength was mildly re-
duced in the entire left leg and proximal right leg. Lower 
limb reﬂ  exes and sensation, as well as cranial nerve and 
upper limb function, were within normal limits. Laboratory 
results of blood tests were within reference ranges.
The next day, MRI was highly suggestive of poliomy-
elitis. It showed a globular pattern of increased signal on 
T2-weighted sequences, limited to the anterior horn region 
throughout the spinal cord, without enhancement with gad-
olinium (Figure 1). The Department of Human Services, 
Victoria, was notiﬁ  ed of the clinical diagnosis of polio-
myelitis; the patient was admitted to a single room, and 
contact precautions were instituted. Panenterovirus reverse 
transcription–PCR (RT-PCR) of feces, serum, and throat 
swab produced negative results, but the samples were for-
warded to the NPRL for cell culture 2 days later (Table). 
Cerebrospinal ﬂ  uid contained 1 × 106 polymorphonuclear 
cells, 8 × 106 lymphocytes, 24 × 106 erythrocytes, a protein 
concentration of 1.9 g/L, and glucose levels within normal 
limits.
Given the patient’s recent history of herpes zoster, in-
travenous acyclovir (10 mg/kg every 8 hours) was begun 
to treat possible varicella zoster virus–related myelitis. The 
patient had recovered completely by 48 hours, and this treat-
ment was stopped. Laboratory identiﬁ  cation of wild polio-
virus type 1 was reported on day 7 after hospital admission, 
5 days after fecal samples were submitted. The patient was 
quarantined in the hospital until 2 fecal specimens taken 7 
days apart were negative for poliovirus by cell culture and 
RT-PCR, a total of 34 days (Table). The public health re-
sponse, directed by the Department of Human Services, in-
cluded vaccination of potentially susceptible persons who 
had been exposed to the index case-patient and home quar-
antine of his household contacts until poliovirus shedding 
was excluded. No secondary cases were identiﬁ  ed.
At the NPRL, the initial fecal specimen was extracted 
according to recommended procedures (5) and incubated 
with 4 continuous mammalian cell lines: L20B, RD-A, 
Hep2 Cincinnati, and human embryonic lung. After 4 days, 
enterovirus cytopathic effect was observed in all cell lines 
except RD-A. This ﬁ  nding was after passage onto fresh cell 
lines to reduce toxicity.
Conﬁ   rmatory testing for enterovirus isolation and 
intratypic differentiation for poliovirus was performed 
(5). The virus was identiﬁ  ed by RT-PCR and ELISA as 
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tive analysis of the virus capsid protein 1 genomic region 
were acquired by using the BLAST algorithm (www.ncbi.
nlm.nih.gov/blast/Blast.cgi). Phylogenetic analysis showed 
a common ancestor with a wild poliovirus isolated from 
Pakistan in 2000 and clustering within a group of isolates 
originating in Pakistan, Afghanistan, and Iran (Figure 2). 
The National Polio Laboratory of Pakistan reported that the 
isolate from Australia had 98.8% nucleotide identity with 
isolates from Pakistan in 2006, which are not available in 
the public domain (S. Zaidi and S. Sharif, pers. comm.).
Acute- and convalescent-phase serum specimens were 
collected on days 15 and 47 after symptom onset, respec-
tively, and tested for total immunoglobulin poliovirus neu-
tralizing antibodies according to recommended methods 
(6). Antibodies to all 3 poliovirus serotypes were detected 
in both specimens. The potency of antibodies to authenti-
cated Sabin poliovirus type 1 was 212 and 424 IU for the 
acute- and convalescent-phase samples, respectively. To 
have determined the titer of neutralizing antibodies at the 
onset of symptoms, earlier collection of acute-phase serum 
would have been needed.
Doubt was cast on the diagnosis of poliomyelitis be-
cause of the patient’s age, vaccination history, and the 
initial panenterovirus PCR–negative fecal specimen. How-
ever, previous vaccination does not exclude poliomyelitis; 
reduced seroconversion to polio vaccine is well described 
in polio-endemic regions (7). Furthermore, although this 
patient had received oral polio vaccine during childhood, 
he received no booster dose before his recent travel.
Several factors support an argument against the nega-
tive predictive value of the initial fecal panenterovirus 
RT-PCR. Fecal shedding of poliovirus by infected per-
sons can be intermittent; hence, 2 fecal specimens from 
suspected case-patients are recommended (5). Panentero-
virus RT-PCR was subsequently positive for the second 
fecal specimen, provided 2 days after the ﬁ  rst. In retro-
spect, the virus titer in the ﬁ  rst specimen may have been 
below the limits of detection for RT-PCR; this limitation 
was overcome by virus multiplication in cell culture. The 
panenterovirus RT-PCR is a heminested assay adapted 
from Zoll et al. (8) by addition of an internal second round 
primer. This assay’s performance in an external proﬁ  -
ciency testing program conducted by the Royal College 
of Pathologists of Australasia (9) has met a high standard. 
Repeat testing of the ﬁ  rst fecal specimen by this assay 
showed 1 of 15 replicates to be positive, consistent with a 
low poliovirus copy number.
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Figure 1.  A) Sagittal image 
of the conus and B) coronal 
image of the cervical cord, 
demonstrating increased signal 
on T2 weighted sequences in 
the region of the anterior horns. 
There was no enhancement 
with contrast.
Table. Virus diagnostic tests for poliovirus conducted for 22-year-old male Pakistani student in Melbourne, Australia, 2007* 
Specimen Time after symptom onset, d  EV RT-PCR  Cell culture  PV1 ELISA  ITD PCR 
Feces 15 Negative Positive PV1NSL PV1 wild 
Swab (throat)  15 Negative Negative
CSF 15 Negative Negative
Feces  17 Positive Positive Not tested  PV1 wild 
Feces 25 Negative Negative
Feces 28 Negative Negative
Feces 30 Negative Negative
Feces 37 Negative Negative
*EV RT-PCR, panenterovirus reverse transcription–PCR for direct detection from original clinical specimen; PV1, poliovirus type 1; ITD PCR, intratypic 
differentiation PCR; PV1NSL, poliovirus type 1 non–Sabin-like; CSF, cerebrospinal fluid.  Imported Poliomyelitis, Melbourne, Australia, 2007
Furthermore, childhood vaccination may have attenu-
ated the duration of virus shedding. Because the travel his-
tory, clinical illness, and radiographic appearance were 
highly suggestive of poliomyelitis, the presumptive diag-
nosis remained poliomyelitis until conﬁ  rmation by fecal 
culture.
Conclusions
Until polio is completely eradicated, polio-free regions 
remain at risk for importation and subsequent transmission 
of poliovirus. Poliomyelitis should be considered in pa-
tients who have acute ﬂ  accid paralysis or a febrile illness 
without an alternate diagnosis and who have travelled from 
countries with endemic poliovirus transmission; neither 
previous vaccination nor a single negative fecal enteroviral 
PCR excludes poliomyelitis. The high level of vaccination 
in Australia reduces the risk for local transmission after 
poliovirus importation. However, Australia has a large mi-
grant population who might not be immune, and Aboriginal 
and Torres Strait Islanders exhibit reduced seroconversion 
rates after polio vaccination (10). Risk for local outbreaks 
can be minimized by widespread vaccination, early recog-
nition of an index case, and prompt and appropriate public 
health measures.
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Figure 2. VP1 phylogenetic tree constructed by using cognate 
sequence available in the public domain was created by using the 
PHYLIP DNA maximum-likelihood algorithm with 100 bootstrap 
replicates. Marker represents relative phylogenetic distance. AFG, 
Afghanistan; AUS, Australia; BAN, Bangladesh; CHN, China; GRE, 
Greece; IND, India; IRA, Iran; NEP, Nepal; PAK, Pakistan; SYR, 
Syria; TAJ, Tajikistan; UZB, Uzbekistan. Scale bar represents 0.1 
nucleotide substitions per site.